↓ Skip to main content

Dove Medical Press

Article Metrics

Changing the face of hepatitis C management – the design and development of sofosbuvir

Overview of attention for article published in Drug Design, Development and Therapy, April 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page
wikipedia
1 Wikipedia page

Citations

dimensions_citation
30 Dimensions

Readers on

mendeley
80 Mendeley
Title
Changing the face of hepatitis C management – the design and development of sofosbuvir
Published in
Drug Design, Development and Therapy, April 2015
DOI 10.2147/dddt.s65255
Pubmed ID
Authors

Andrew Delemos, Bennett Noell, Siddesh Besur

Abstract

The availability of direct-acting antiviral (DAA) therapy has launched a new era in the management of chronic hepatitis C. Sofosbuvir, a uridine nucleotide analog that inhibits the hepatitis C RNA-dependent RNA polymerase, is the backbone of chronic hepatitis C therapy. Acting at the catalytic site of the polymerase, sofosbuvir is highly potent in suppressing viral replication and has a high genetic barrier to resistance. Sofosbuvir is effective across all hepatitis C genotypes, and is a mainstay of interferon-free combination therapy. In Phase II and III studies, genotype 1 patients who took sofosbuvir in combination with another DAA such as the NS3-4A protease inhibitor, simeprevir, or the NS5A replication complex inhibitors, ledipasvir or daclatasvir, achieved a sustained virologic response rate of over 90%. Harvoni(®), a combination tablet of sofosbuvir and ledipasvir, dosed once daily is recommended for 24 weeks for treatment-experienced genotype 1 patients with cirrhosis, but 12 weeks of therapy is sufficient for all other populations. While genotype 2 (12 weeks or 16 weeks) and treatment-naïve genotype 3 patients (24 weeks) have excellent response rates with sofosbuvir and ribavirin, treatment-experienced cirrhotic genotype 3 patients may need the addition of another DAA such as daclatasvir. Sofosbuvir is efficacious in special populations such as HIV-hepatitis C virus-coinfected patients and liver transplant recipients and has already made a profound impact in these groups. Since it is renally eliminated, patients with advanced kidney disease or on dialysis must await dosing recommendations. Sofosbuvir-based regimens appear to be well tolerated with headache and fatigue being the most common side effects. The opportunity to cure patients with hepatitis C with sofosbuvir combination therapy is likely to change the future for our patients, particularly if the emphasis shifts to identifying those patients unaware that they are infected and providing affordable access to treatment.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 1%
United States 1 1%
Unknown 78 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 18%
Student > Master 12 15%
Student > Bachelor 12 15%
Student > Ph. D. Student 9 11%
Other 9 11%
Other 13 16%
Unknown 11 14%
Readers by discipline Count As %
Medicine and Dentistry 31 39%
Agricultural and Biological Sciences 8 10%
Pharmacology, Toxicology and Pharmaceutical Science 5 6%
Chemistry 4 5%
Biochemistry, Genetics and Molecular Biology 3 4%
Other 13 16%
Unknown 16 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 September 2018.
All research outputs
#6,320,293
of 20,867,471 outputs
Outputs from Drug Design, Development and Therapy
#403
of 1,936 outputs
Outputs of similar age
#74,425
of 245,586 outputs
Outputs of similar age from Drug Design, Development and Therapy
#31
of 148 outputs
Altmetric has tracked 20,867,471 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 1,936 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 245,586 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 148 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.